Head-to-head evidence
CJ-30060 vs CJ-30061
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Hypertension
Shared mechanism: Angiotensin II receptor / Calcium channel / HMG-CoA reductase · full Hypertension pipeline
CJ-30060
Developed by HK inno.N Corporation
NCT03536598 · Phase 3 · completed
The trial randomly assigned 203 participants and used quadruple blinding with two active comparator groups. Its primary endpoints were changes in LDL-C and sitting systolic blood pressure at 8 weeks, but no results or statistical comparisons are posted, so the primary endpoint cannot be judged as met or missed.
CJ-30061
Developed by HK inno.N Corporation
NCT03639480 · Phase 3 · status unknown
The trial is randomized, blinded, and actively controlled, and measures blood pressure and LDL cholesterol, both accepted clinical endpoints for these conditions. However, results have not been posted yet, so whether the triple combination outperformed the two-drug regimens is unknown.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: CJ-30060's landscape · CJ-30061's landscape